Ipilimumab and Nivolumab in patients with neuroendocrine carcinomas: Two case reports

#3134

Introduction: Neuroendocrine carcinomas (NEC) have a poor prognosis and there is no standard second-line treatment. Two studies, DART SWOG 1609 and CA209-538, have shown activity of the combination of Ipilimumab and Nivolumab.

Aim(s): We report data from the first two patients with NEC treated with immunotherapy combinations in our centre after progression despite previous platinum-etoposide treatment.

Materials and methods: Case report and literature review will be presented.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Folgueira Hernandez B, Lafuente A, De Frutos B, De La Torre S, Catoya J,

Keywords: neuroendocrine carcinoma, Nivolumab, Ipilimumab,